

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

February 7, 2019

Patrick Fabbio Senior Vice President and Chief Financial Officer Progenics Pharmaceuticals Inc. One World Trade Center, 47th Floor New York, NY 10007

> Re: Progenics Pharmaceuticals Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Filed March 8, 2018 File No. 000-23143

Dear Mr. Fabbio:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Healthcare & Insurance